EUVIMEDEUVIMED entdecken
Crossref

Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis

María José Mela Osorio, Beatriz Moiraghi, María Victoria Osycka, Miguel A Pavlovsky, Ana Inés Varela, Georgina Emilia Bendek Del Prete, María Fernanda Tosin, Mariel Ana Pérez, María Elisa Riva, Roxana Ramírez Berrios, Isolda Fernández, Federico Sackmann Massa und 3 weitere

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2023.10.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von María José Mela Osorio und 14 weiteren Autor:innen. Beteiligte Einrichtung: Fundaleu - Fundación para combatir la leucemia, Buenos Aires, Argentina. Electronic address: mjmela@fundaleu.org.ar. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Pyridazines, Imidazoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ponatinib is a third-generation tyrosine-kinase inhibitor (TKI), indicated in patients with chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML), who are resistant or intolerant to ≥2 prior TKIs, patients for whom subsequent treatment with imatinib is not appropriate, and patients who have a T315I mutation. PATIENTS AND METHODS: We aimed to evaluate outcomes of ponatinib treatment, including safety, with focus on cardiovascular toxicity, in real-world patients from Argentina. Data from patients with CP CML treated with ponatinib was retrospectively retrieved from 2013 to 2023 in 7 centers. RESULTS: Seventy-two patients were included (median age: 44 years; male: 55.5%; T315I mutation: 32%: median treatment duration: 36 months. At baseline, 57 patients (79%) had a breakpoint cluster region-Abelson (BCR::ABL1) transcript level >10% on the international reporting scale (BCR::ABL1 IS). A molecular response (MR, BCR::ABL1 (IS) 2% were significantly associated with higher risk of AOEs. Controlling CV risk factors and reducing doses at optimal time points may help to optimize ponatinib use in daily practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositivePyridazinesImidazolesHumansMaleAdultFollow-Up StudiesRetrospective StudiesBlast CrisisFusion Proteins, bcr-ablProtein Kinase Inhibitors

Stichwörter der Autor:innen

ArgentinaCMLThird Generation TKI

Substanzen

ponatinibAntineoplastic AgentsPyridazinesFusion Proteins, bcr-ablProtein Kinase InhibitorsImidazoles

Autor:innen und Institutionen

  • Fundaleu - Fundación para combatir la leucemia, Buenos Aires, Argentina. Electronic address: mjmela@fundaleu.org.ar.
  • Hospital General de Agudos José María Ramos Mejía, Buenos Aires, Argentina.
  • Fundaleu - Fundación para combatir la leucemia, Buenos Aires, Argentina.
  • Hospital Italiano de San Justo Agustín Rocca, San Justo, Argentina.
  • Hospital de Alta Complejidad El Cruce Néstor Kirchner, Florencio Varela, Argentina.
  • Hospital Interzonal General de Agudos Profesor Dr. Rodolfo Rossi, La Plata, Argentina.

Zitieren

APA

Mela Osorio, M. J., Moiraghi, B., Osycka, M. V., Pavlovsky, M. A., Varela, A. I., Bendek Del Prete, G. E., Tosin, M. F., Pérez, M. A., Riva, M. E., Berrios, R. R., Fernández, I., Sackmann Massa, F., Giere, I., Sighel, C., & Pavlovsky, C. (2024). Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.10.008

Vancouver

Mela Osorio MJ, Moiraghi B, Osycka MV, Pavlovsky MA, Varela AI, Bendek Del Prete GE, et al. Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2023.10.008

BibTeX
@article{MelaOsorio2024,
  author = {Mela Osorio, María José and Moiraghi, Beatriz and Osycka, María Victoria and Pavlovsky, Miguel A and Varela, Ana Inés and Bendek Del Prete, Georgina Emilia and Tosin, María Fernanda and Pérez, Mariel Ana and Riva, María Elisa and Berrios, Roxana Ramírez and Fernández, Isolda and Sackmann Massa, Federico and Giere, Isabel and Sighel, Carolina and Pavlovsky, Carolina},
  title = {Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2023.10.008}
}
Kostenlos starten →